FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2195373199> ?p ?o ?g. }

• W2195373199 endingPage "557.e2" @default.
• W2195373199 startingPage "550" @default.
• W2195373199 abstract "Background & AimsIt is not clear what serum levels of anti–tumor necrosis factor are associated with reduced intestinal inflammation in patients with inflammatory bowel disease (IBD). We aimed to identify serum levels of infliximab and adalimumab associated with mucosal healing in patients with IBD and to evaluate the putative gain in control of inflammation by incremental increases in drug levels.MethodsWe performed a retrospective cross-sectional study of 145 patients with IBD treated with infliximab (n = 78) or adalimumab (n = 67) at a medical center in Israel from 2009 through 2014. We collected data from colonoscopy examinations; mucosal healing was defined as simple endoscopic score of <3 or a Mayo score ≤1. These data were compared with serum levels of anti–tumor necrosis factor agents, clinical scores, and levels of C-reactive protein.ResultsMedian serum levels of infliximab and adalimumab were significantly higher in patients with mucosal healing than patients with active disease (based on endoscopy) (for infliximab, 4.3 vs 1.7 μg/mL, P = .0002; for adalimumab, 6.2 vs 3.1 μg/mL, P = .01). Levels of infliximab above 5 μg/mL (area under the curve = 0.75; P < .0001) and levels of adalimumab above 7.1 μg/mL (area under the curve = 0.7; P = .004) identified patients with mucosal healing with 85% specificity. Increasing levels of infliximab beyond 8 μg/mL produced only minimal increases in the rate of mucosal healing, whereas the association between higher level of adalimumab and increased rate of mucosal healing reached a plateau at 12 μg/mL. In patients with measurable levels of infliximab >3 μg/mL, the presence of antibodies to infliximab was associated with a lower rate of mucosal healing compared with patients with similar drug level without antibodies (16% vs 50%, respectively; P = .003).ConclusionsIn a retrospective study, we found significant association between serum levels of anti–tumor necrosis factor agents and level of mucosal healing. We propose that serum levels of 6–10 μg/mL for infliximab and 8–12 μg/mL for adalimumab are required to achieve mucosal healing in 80%–90% of patients with IBD, and that this could be considered as a “therapeutic window.” Exceeding these levels produces only a negligible gain in proportion of patients with mucosal healing. It is not clear what serum levels of anti–tumor necrosis factor are associated with reduced intestinal inflammation in patients with inflammatory bowel disease (IBD). We aimed to identify serum levels of infliximab and adalimumab associated with mucosal healing in patients with IBD and to evaluate the putative gain in control of inflammation by incremental increases in drug levels. We performed a retrospective cross-sectional study of 145 patients with IBD treated with infliximab (n = 78) or adalimumab (n = 67) at a medical center in Israel from 2009 through 2014. We collected data from colonoscopy examinations; mucosal healing was defined as simple endoscopic score of <3 or a Mayo score ≤1. These data were compared with serum levels of anti–tumor necrosis factor agents, clinical scores, and levels of C-reactive protein. Median serum levels of infliximab and adalimumab were significantly higher in patients with mucosal healing than patients with active disease (based on endoscopy) (for infliximab, 4.3 vs 1.7 μg/mL, P = .0002; for adalimumab, 6.2 vs 3.1 μg/mL, P = .01). Levels of infliximab above 5 μg/mL (area under the curve = 0.75; P < .0001) and levels of adalimumab above 7.1 μg/mL (area under the curve = 0.7; P = .004) identified patients with mucosal healing with 85% specificity. Increasing levels of infliximab beyond 8 μg/mL produced only minimal increases in the rate of mucosal healing, whereas the association between higher level of adalimumab and increased rate of mucosal healing reached a plateau at 12 μg/mL. In patients with measurable levels of infliximab >3 μg/mL, the presence of antibodies to infliximab was associated with a lower rate of mucosal healing compared with patients with similar drug level without antibodies (16% vs 50%, respectively; P = .003). In a retrospective study, we found significant association between serum levels of anti–tumor necrosis factor agents and level of mucosal healing. We propose that serum levels of 6–10 μg/mL for infliximab and 8–12 μg/mL for adalimumab are required to achieve mucosal healing in 80%–90% of patients with IBD, and that this could be considered as a “therapeutic window.” Exceeding these levels produces only a negligible gain in proportion of patients with mucosal healing." @default.
• W2195373199 created "2016-06-24" @default.
• W2195373199 creator A5004944892 @default.
• W2195373199 creator A5005564075 @default.
• W2195373199 creator A5035713128 @default.
• W2195373199 creator A5038695710 @default.
• W2195373199 creator A5047907008 @default.
• W2195373199 creator A5054612550 @default.
• W2195373199 creator A5056533442 @default.
• W2195373199 creator A5062860652 @default.
• W2195373199 creator A5065046461 @default.
• W2195373199 creator A5080002704 @default.
• W2195373199 creator A5089704358 @default.
• W2195373199 date "2016-04-01" @default.
• W2195373199 modified "2023-10-18" @default.
• W2195373199 title "Optimizing Anti-TNF-α Therapy: Serum Levels of Infliximab and Adalimumab Are Associated With Mucosal Healing in Patients With Inflammatory Bowel Diseases" @default.
• W2195373199 cites W1965832974 @default.
• W2195373199 cites W1968655366 @default.
• W2195373199 cites W1991810959 @default.
• W2195373199 cites W1998974262 @default.
• W2195373199 cites W2003835888 @default.
• W2195373199 cites W2003904406 @default.
• W2195373199 cites W2006396734 @default.
• W2195373199 cites W2020350753 @default.
• W2195373199 cites W2022661087 @default.
• W2195373199 cites W2034008046 @default.
• W2195373199 cites W2034892783 @default.
• W2195373199 cites W2034939253 @default.
• W2195373199 cites W2038017077 @default.
• W2195373199 cites W2040181440 @default.
• W2195373199 cites W2054755479 @default.
• W2195373199 cites W2057003221 @default.
• W2195373199 cites W2060838174 @default.
• W2195373199 cites W2078032211 @default.
• W2195373199 cites W2081061562 @default.
• W2195373199 cites W2102245241 @default.
• W2195373199 cites W2105159981 @default.
• W2195373199 cites W2106072130 @default.
• W2195373199 cites W2115112939 @default.
• W2195373199 cites W2115487750 @default.
• W2195373199 cites W2118088660 @default.
• W2195373199 cites W2134803931 @default.
• W2195373199 cites W2136589391 @default.
• W2195373199 cites W2171297959 @default.
• W2195373199 cites W2333994998 @default.
• W2195373199 cites W2615184173 @default.
• W2195373199 doi "https://doi.org/10.1016/j.cgh.2015.10.025" @default.
• W2195373199 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26538204" @default.
• W2195373199 hasPublicationYear "2016" @default.
• W2195373199 type Work @default.
• W2195373199 sameAs 2195373199 @default.
• W2195373199 citedByCount "293" @default.
• W2195373199 countsByYear W21953731992015 @default.
• W2195373199 countsByYear W21953731992016 @default.
• W2195373199 countsByYear W21953731992017 @default.
• W2195373199 countsByYear W21953731992018 @default.
• W2195373199 countsByYear W21953731992019 @default.
• W2195373199 countsByYear W21953731992020 @default.
• W2195373199 countsByYear W21953731992021 @default.
• W2195373199 countsByYear W21953731992022 @default.
• W2195373199 countsByYear W21953731992023 @default.
• W2195373199 crossrefType "journal-article" @default.
• W2195373199 hasAuthorship W2195373199A5004944892 @default.
• W2195373199 hasAuthorship W2195373199A5005564075 @default.
• W2195373199 hasAuthorship W2195373199A5035713128 @default.
• W2195373199 hasAuthorship W2195373199A5038695710 @default.
• W2195373199 hasAuthorship W2195373199A5047907008 @default.
• W2195373199 hasAuthorship W2195373199A5054612550 @default.
• W2195373199 hasAuthorship W2195373199A5056533442 @default.
• W2195373199 hasAuthorship W2195373199A5062860652 @default.
• W2195373199 hasAuthorship W2195373199A5065046461 @default.
• W2195373199 hasAuthorship W2195373199A5080002704 @default.
• W2195373199 hasAuthorship W2195373199A5089704358 @default.
• W2195373199 hasBestOaLocation W21953731991 @default.
• W2195373199 hasConcept C121608353 @default.
• W2195373199 hasConcept C126322002 @default.
• W2195373199 hasConcept C17991360 @default.
• W2195373199 hasConcept C2777138892 @default.
• W2195373199 hasConcept C2778260677 @default.
• W2195373199 hasConcept C2778435480 @default.
• W2195373199 hasConcept C2779134260 @default.
• W2195373199 hasConcept C2779280984 @default.
• W2195373199 hasConcept C2780132546 @default.
• W2195373199 hasConcept C2780479503 @default.
• W2195373199 hasConcept C526805850 @default.
• W2195373199 hasConcept C71924100 @default.
• W2195373199 hasConcept C90924648 @default.
• W2195373199 hasConceptScore W2195373199C121608353 @default.
• W2195373199 hasConceptScore W2195373199C126322002 @default.
• W2195373199 hasConceptScore W2195373199C17991360 @default.
• W2195373199 hasConceptScore W2195373199C2777138892 @default.
• W2195373199 hasConceptScore W2195373199C2778260677 @default.
• W2195373199 hasConceptScore W2195373199C2778435480 @default.
• W2195373199 hasConceptScore W2195373199C2779134260 @default.
• W2195373199 hasConceptScore W2195373199C2779280984 @default.
• W2195373199 hasConceptScore W2195373199C2780132546 @default.
• W2195373199 hasConceptScore W2195373199C2780479503 @default.
• W2195373199 hasConceptScore W2195373199C526805850 @default.

• next